Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adaptimmune And Astellas Team Up For Off-The-Shelf T-Cell Therapies

Could Be Worth $900m

Executive Summary

News of the deal emerged as the UK firm's shares skyrocketed after its SPEAR T-cell platform delivered responses in four solid tumor types.

You may also be interested in...



ASCO: Presentations Showcase Possibilities Of Next-Generation Cell Therapies

An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.

Adaptimmune ‘Neck And Neck’ For First Solid Tumor T-Cell Therapy Nod For Afami-Cel

The company’s CEO and chief medical officer talked about some challenges as well as opportunities and what they have learned from the experience of other cell therapies.

Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko

Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel